Vilin Bio Med IPO | Apply or not? | SME IPO | latest news | GMP | Complete review
Incorporated in 2005, Vilin Bio Med Limited is engaged in the domestic business of manufacturing pharmaceutical products, and the manufacturing unit.
The company sells its products in bulk to pharmaceutical manufacturers, marketers, and traders, who provide the channel for sales to customers.
Its product list can be classified into:
Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non-βeta-Lactam).
Tablets & Capsules (βeta & Non-βeta-Lactam).
External Preparations.
Dry Powders.
The company has its R&D foundation and manufacturing facility in Roorkee, Uttarakhand.
Vilin Bio Med recorded a Rs. 1,121.91 Lakhs revenue in the year 2022, and Rs. 1,171.88 Lakhs in the year 2021.
Vilin Bio Med IPO
Vilin Bio Med sme IPO
Vilin Bio Med ltd IPO
#ipo2023 #latestiponews #ipo #technicalanalysis #fundamentalanalysis #smeipo
LEGAL DISCLAIMER:
Use of this information is at the user's own risk. I and employees will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided herein. The investment discussed or views expressed herein may not be suitable for all investors. The users should rely on their own research and analysis and should consult their investment advisors to determine the merit, risks and suitability of recommendation. Past performance is not a guarantee for future performance or future results. Information herein is believed to be reliable, although its accuracy and completeness cannot be guaranteed.
DISCLOSURES UNDER SEBI (RESEARCH ANALYST) REGULATIONS, 2014:
Naveen Kumar Choudhary is registered with SEBI under SEBI (Research Analyst) Regulations, 2014.
Disclosure with regard to ownership and material conflicts of interest
1. Neither Research Analyst nor the entity nor his associates or relatives have any financial interest in the subject Company;
2. Neither Research Analyst nor the entity nor its associates or relatives have actual / beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report or date of public appearance;
3. Neither Research Analyst nor the entity nor its associates or his relatives have any other material conflict of interest at the time of publication of the research report or at the time of public appearance.
Disclosure with regard to receipt of Compensation
1. The Research Entity and its associates have not received compensation from the subject company in the past twelve months.
2. The subject company is not or was not a client during the twelve months preceding the date of recommendation.